CVS' Future Has Never Looked Brighter

After the company posted strong revenue gains but missed earnings estimates, shares inched up a bit. Can CVS continue to be the dominant drugstore chain or should investors check out Rite Aid or Walgreen instead?

May 7, 2014 at 9:52AM

Picture

Source: CVS. 

Even though the company missed analysts' earnings-per-share forecasts, shares of CVS Caremark (NYSE:CVS) inched up 1% to close at $73.86 after it reported a positive revenue surprise. In spite of management's inability to generate the profits that Mr. Market wanted to see, does CVS make for a sensible long-term investment or would Rite Aid (NYSE:RAD) or Walgreen (NASDAQ:WBA) be more attractive opportunities?

CVS' mixed quarter may have some investors concerned
For the quarter, CVS reported revenue of $32.69 billion. On top of beating the $32.31 billion that investors had anticipated, the company reported revenue that was 6% higher than its year-ago figure of $30.76 billion. In its release, CVS attributed the rise in sales to a combination of increased store count and higher comparable-store sales.

During the quarter, comparable-store sales climbed 1.4%. This increase stemmed from a 3.8% jump in pharmacy comparable-store sales but it was negatively affected by a 3.8% decline in front-end comparable-store sales as severe winter weather and a milder flu season hurt the business's performance. As of the end of the quarter, the company operated 7,675 stores, up almost 2% from the 7,531 locations in operation during the first quarter of 2013.

Picture

Source: CVS.

From a profitability perspective, CVS' performance wasn't so hot. For the quarter, the company reported earnings per share of $0.95, 9% below the $1.04 that analysts had anticipated. Even though this was a pretty large miss, the business did succeed in beating the $0.77 per share it earned in the same quarter of last year.

In its earnings release, the company attributed the rise in earnings to its higher revenue but also chalked it up to its operating expenses falling from 12.6% of sales to 12%. Another contributor appeared to be CVS' share count, which declined 4% from the year-ago period.

How does CVS look in comparison with its rivals?
Over the past five years, CVS has been nothing short of a growth machine. Between 2009 and 2013, the drugstore chain's revenue rose 29% from $98.2 billion to $126.8 billion. This rapid growth resulted, in part, from an 8% jump in store count, but the largest contributor to the company's revenue growth was its comparable-store sales, which rose an aggregate 18% during this five-year period. This increase in sales was accompanied by a big improvement in net income, which rose 24% from $3.7 billion to $4.6 billion on higher revenue, but higher costs also negatively affected the company's performance.

Walgreen also demonstrated growth during this time frame, but it was nowhere near what CVS delivered to investors. Between 2009 and 2013, Walgreen's revenue rose a modest 14% from $63.3 billion to $72.2 billion, driven almost entirely by a 14% jump in the number of locations in operation.

CVS Revenue (Annual) Chart

CVS Revenue (Annual) data by YCharts.

Meanwhile, the company's timid comparable-store sales growth of 2% helped, but it didn't come even close to that of CVS. This increase in sales, combined with the share of profits the company received from Alliance Boots, helped push Walgreen's net income up 22% from $2 billion to $2.45 billion.

Undoubtedly, the worst player in the drugstore space over the past five years has been Rite Aid. During this period, the company's revenue declined nearly 1% from $25.7 billion to $25.5 billion. Unlike its rivals, Rite Aid had to close stores (4% of them) in an effort to reduce costs and change its business from a money-losing one into a profitable enterprise.

Fortunately, Rite Aid's falling sales were cushioned by a 0.8% increase in comparable-store sales over this period. Although this looks bad when placed next its peers's results, Rite Aid's management team was able to restructure the company to turn its net loss of $506.7 million into a gain of $249.4 million.

Foolish takeaway
Right now, CVS is not only the largest drugstore chain in the business, it's also the fastest-growing one and it has shown enviable profit growth. For these reasons, it's hard to dismiss it as an investment prospect. In fact, with its historical performance, the company might be a very attractive long-term pick for investors who are looking for a strong market leader. However, for those looking to buy into smaller businesses that are in the process of improving their metrics, both Walgreen and Rite Aid might make for nice alternatives.

Top dividend stocks for the next decade
On top of phenomenal growth over the long run, CVS has continued to reward investors with dividends. Does the company have what it takes to maintain this dividend or are there other players out there with more appealing prospects?

The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Daniel Jones has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers